Jurgen Corthals
Overview
Explore the profile of Jurgen Corthals including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jansen Y, Kruse V, Corthals J, Schats K, Van Dam P, Seremet T, et al.
Cancer Immunol Immunother
. 2020 Jun;
69(12):2589-2598.
PMID: 32591862
Background: Autologous monocyte-derived mRNA co-electroporated dendritic cells with mRNA encoding CD40 ligand (CD40L), CD70 and a constitutively activated TLR4 (caTLR4) (referred to as TriMixDC-MEL) have anti-tumor activity in advanced melanoma...
2.
De Keersmaecker B, Claerhout S, Carrasco J, Bar I, Corthals J, Wilgenhof S, et al.
J Immunother Cancer
. 2020 Mar;
8(1).
PMID: 32114500
Background: We previously reported that dendritic cell-based mRNA vaccination plus ipilimumab (TriMixDC-MEL IPI) results in an encouraging rate of tumor responses in patients with pretreated advanced melanoma. Here, we report...
3.
Broos K, Lecocq Q, De Keersmaecker B, Raes G, Corthals J, Lion E, et al.
Vaccines (Basel)
. 2019 Aug;
7(3).
PMID: 31394834
Dendritic cell [DC] vaccines can induce durable clinical responses, at least in a fraction of previously treated, late stage cancer patients. Several preclinical studies suggest that shielding programmed death-ligand 1...
4.
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
Broos K, Lecocq Q, Xavier C, Bridoux J, Nguyen T, Corthals J, et al.
Cancers (Basel)
. 2019 Jun;
11(6).
PMID: 31234464
The PD-1:PD-L1 immune checkpoint axis is central in the escape of cancer cells from anticancer immune responses. Monoclonal antibodies (mAbs) specific for PD-L1 have been approved for treatment of various...
5.
Fostier K, Caers J, Meuleman N, Broos K, Corthals J, Thielemans K, et al.
Oncotarget
. 2018 May;
9(29):20476-20489.
PMID: 29755666
Lenalidomide is a potent anti-myeloma drug with immunomodulatory properties. It is increasingly used in a low-dose maintenance setting to prolong remission duration after standard treatment. Data on the effects of...
6.
Coosemans A, Tuyaerts S, Morias K, Corthals J, Heirman C, Thielemans K, et al.
Methods Mol Biol
. 2016 May;
1428:277-83.
PMID: 27236806
The immune system is a crucial player in the development of cancer. Once it is in imbalance and immunosuppressive mechanisms supporting tumor growth take over control, dendritic cell immunotherapy might...
7.
Wilgenhof S, Corthals J, Heirman C, van Baren N, Lucas S, Kvistborg P, et al.
J Clin Oncol
. 2016 Mar;
34(12):1330-8.
PMID: 26926680
Purpose: Autologous monocyte-derived dendritic cells (DCs) electroporated with synthetic mRNA (TriMixDC-MEL) are immunogenic and have antitumor activity as a monotherapy in patients with pretreated advanced melanoma. Ipilimumab, an immunoglobulin G1...
8.
Wilgenhof S, Corthals J, Van Nuffel A, Benteyn D, Heirman C, Bonehill A, et al.
Cancer Immunol Immunother
. 2014 Dec;
64(3):381-8.
PMID: 25548092
Purpose: Melanoma patients with a high risk of recurrence may benefit from immunotherapy with mRNA-electroporated autologous monocyte-derived dendritic cells (DCs). Further benefit may be found in combining DC-therapy with interferon...
9.
Maenhout S, Du Four S, Corthals J, Neyns B, Thielemans K, Aerts J
Oncotarget
. 2014 Aug;
5(16):6801-15.
PMID: 25149535
AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase which inhibits STAT3 phosphorylation and tumor growth. Here we investigated the effects of AZD1480 on the function of different immune...
10.
De Keersmaecker B, Fostier K, Corthals J, Wilgenhof S, Heirman C, Aerts J, et al.
Cancer Immunol Immunother
. 2014 Jun;
63(10):1023-36.
PMID: 24947180
Multiple myeloma (MM) is characterized by a malignant proliferation of plasma cells in the bone marrow with associated organ damage. Although the prognosis of MM has improved recently, the disease...